STATUE: The set of detection signals collected for each patient was then analyzed using ML to screen the patient for PCa. Seventy-six urine samples were measured three times, generating 912 … display Lake
Credit: Korea Institute of Science and Technology (KIST)
Prostate cancer is one of the most common cancers in men. Patients are determined to have prostate cancer, mainly based on * PSA, a cancer factor in blood. However, since the diagnostic accuracy is as low as 30%, a significant number of patients undergo additional invasive biopsy and suffer the resulting side effects such as bleeding and pain.
* Prostate specific antigen (PSA): a prostate specific antigen (a cancer factor) used as an index for prostate cancer screening.
The Korea Institute of Science and Technology (KIST) announced that the joint research team led by Dr Kwan Hyi Lee of the Biomaterials Research Center and Professor In Gab Jeong of Asan Medical Center has developed a technique to extract prostate cancer from urine within 20 minutes. diagnose. with almost 100% accuracy. The research team developed this technique by introducing a smart AI analysis method in an electrical signal-based ultra-sensitive biosensor.
Being a non-invasive method, a diagnostic test that uses urine is convenient for patients and does not require an invasive biopsy, diagnosing cancer without side effects. However, because the concentration of cancer ** factors in the urine is low, a urine-based biosensor has so far been used to classify risk groups rather than for an accurate diagnosis.
** Cancer Factor: A cancer-related biological index that can objectively measure and evaluate drug reactivity for normal biological process, disease progression, and treatment method.
Dr. Lee at the KIST has been working to develop a technique for diagnosing disease from urine using the electrical signal-based ultra-sensitive biosensor. An approach using a single cancer factor associated with a cancer diagnosis was limited in increasing the accuracy of the diagnosis to more than 90%. To overcome this limitation, the team used several types of cancer factors at the same time, rather than just one, to innovatively improve diagnostic accuracy.
The team developed an ultra-sensitive semiconductor sensor system capable of simultaneously measuring traces of selected four cancer factors in urine for the diagnosis of prostate cancer. They trained AI using the correlation between the four cancer factors, which were obtained from the developed sensor. The trained AI algorithm was then used to identify people with prostate cancer by analyzing complex patterns of the detected signals. The diagnosis of prostate cancer using the AI analysis successfully detected 76 urine samples with almost 100 percent accuracy.
“For patients requiring surgery and / or treatment, cancer will be diagnosed with high accuracy by using urine to minimize unnecessary biopsies and treatments, which can dramatically reduce medical costs and medical staff fatigue,” said Professor Jeong from Asan Medical Center. “This research has developed a smart biosensor that can quickly diagnose prostate cancer with almost 100 percent accuracy, only through a urine test, and it can be further used in the precise diagnosis of other cancers using a urine test,” said Dr. Lee from the CASH. .
###
This research was supported by the Korean National Research Foundation’s Midcareer Researcher Grant Program, government departments (Ministry of Science and ICT, Ministry of Trade and Industry, Ministry of Health and Welfare and Ministry of Food and Drug Safety), and Korea Medical Device Development Fund, funded by the Ministry of Science and ICT (MSIT). The research results are published in the latest issue of ACS Nano, an international top academic journal on nanofield.
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of any press release posted on EurekAlert! by contributing institutions or for the use of information through the EurekAlert system.